Summary Toshiba America Medical Systems Inc (TAMS), a subsidiary of Toshiba Medical Systems Corp, is a medical device company which markets and distributes the diagnostic imaging systems. The company offers cardiovascular X-ray, computed tomography, angiography, magnetic resonance, ultrasound and x-ray products.
TAMS offer services such as rapid response, service agreements, service commitment, enterprise integration, image marker login, institute of advanced, archived webinars, angiography, magnetic resonance, onsite training and installation. Its angiography products find application in the segments such as interventional cardiology, oncology and radiology; pediatrics and neuro-radiology. The company through its Toshiba Learning Center (TLC) provides access for both online and instructor led courses. TAMS is headquartered in Tustin, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Toshiba America Medical Systems Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Our reports have been used by over 10K customers, including:
Global TIGIT Inhibitor Drug Opportunity & Clinical Research Insight 2022 Report Highlights: • Global TIGIT Inhibitor Market Dynamics • Clinical Approaches to Target TIGIT • Role of TIGIT Inhibitors in Cancer, HIV, Autoimmune Disorders • Number of TIGIT Inhibitor Drug In Trials • TIGIT Inhibitors Trials...
The global eClinical Solutions market is projected to reach USD 15.4 billion by 2026 from USD 8.3 billion in 2021 at a CAGR of 13.3%. Increasing operational costs and regulatory requirements associated with clinical research studies, government grants to support clinical trials, and growing R&D expenditure on drug development by pharma-biotech...
Hypereosinophilic Syndrome (Hematology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hypereosinophilic Syndrome - Drugs In Development, 2021, provides an overview of the Hypereosinophilic Syndrome (Hematological Disorders) pipeline landscape.The...
Chikungunya Fever (Infectious Disease) - Drugs In Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Drugs In Development, 2021, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.Chikungunya is a viral...
Coronavirus Disease 2019 (COVID-19) Vaccines and Drugs Contract Pharmaceutical Development and Manufacturing Relationships Summary This report is the companion to Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion (July 2020).IT...
The analyst presents post–COVID-19 growth opportunities and strategic imperatives for the global decentralized clinical trials (DCT) market, covering the market’s maturity, key participants, adoption drivers and restraints, and recent mergers and acquisitions. The report identifies initiatives by major global contract research organizations...
The ePRO, ePatient Diaries, and eCOA market in Middle East and Africa is expected to grow from US$ 48.4 million in 2021 to US$ 112.3 million by 2028; it is estimated to grow at a CAGR of 12.8% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. Mobile-enabled...
The ePRO, ePatient Diaries, and eCOA market in North America is expected to grow from US$ 607.2 million in 2021 to US$ 1,640.6 million by 2028; it is estimated to grow at a CAGR of 15.3% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. As per the...
Health Provider Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.